Dr William Victor Fattig, MD | |
723 Flack Ave, Alliance, NE 69301-3514 | |
(308) 225-4498 | |
(308) 629-1499 |
Full Name | Dr William Victor Fattig |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 26 Years |
Location | 723 Flack Ave, Alliance, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811071442 | NPI | - | NPPES |
200269730A | Other | KS | KANSAS MEDICAID |
28D1030805 | Other | NE | CLIA |
35808 | Other | NE | MIDLANDS |
P00181202 | Other | NE | RR MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 21201 (Nebraska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Box Butte General Hospital | Alliance, NE | Hospital |
Regional West Medical Center | Scottsbluff, NE | Hospital |
Morrill County Community Hospital | Bridgeport, NE | Hospital |
Highland Park Care Center | Alliance, NE | Nursing home |
Mailing Address | Practice Location Address |
---|---|
Dr William Victor Fattig, MD 723 Flack Ave, Alliance, NE 69301-3514 Ph: (308) 225-4498 | Dr William Victor Fattig, MD 723 Flack Ave, Alliance, NE 69301-3514 Ph: (308) 225-4498 |
News Archive
Researchers in the United States say the "spiritual" effects of sacred mushrooms can last for more than a year.
The Musculoskeletal Transplant Foundation (MTF) today announced its partnership with the American Society of Plastic Surgeons (ASPS) and the Plastic Surgery Foundation (The PSF) in support of the first national Breast Reconstruction Awareness (BRA) Day USA on October 17, 2012.
Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).
Duke University researchers have now shown that selectively killing the population of regulatory T cells in cancer patients - cells that normally function to restrain the activity of the immune response - improves the ability of a cancer vaccine to stimulate tumor-specific T cells.
› Verified 8 days ago
Mrs. Kristine Renee Maggi, PA-C Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2091 Box Butte Ave Ste 700, Alliance, NE 69301 Phone: 308-762-7244 Fax: 308-761-1249 |